Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lopinavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lopinavir SCHEMBL673770 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL825826 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL28365789 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL13065521 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL18898529 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL3042268 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL13370718 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL22241592 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL22382744 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL12270816 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 32390 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139035-A1 | HUMAN ANTIBODY AGAINST CORONAVIRUS VARIANTS OR ANTIGEN-BINDING FRAGMENT THEREOF | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2026-05-21 | — | — | US | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-2026101812-A1 | HIV INTEGRASE INHIBITORS FOR TREATMENT OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-15 | — | — | WO | claimed |
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260124290-A1 | HIV Immunogens, Vaccines, and Methods Related Thereto | UNIV EMORY (US) | 2026-05-07 | — | — | US | claimed |
| WO-2002056861-A2 | SYNTACTIC DEFORMABLE FOAM COMPOSITIONS AND METHODS FOR MAKING | INTELLIPHARMACEUTICS CORP. (CA) | 2002-07-25 | — | — | WO | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| US-20020090445-A1 | Containing lopinavir or its mixtures, comprising a sweetener, two or more flavoring agents menthol, peppermint, vanilla, cotton candy flavors, and flavor modifier such as sodium citrate, sodium chloride and citric acid | ABBVIE INC. | 2002-07-11 | — | — | US | claimed |
| US-20020055483-A1 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections | PHARMASSET, INC. | 2002-05-09 | — | — | US | claimed |
| WO-2002033402-A2 | ESTABLISHMENT OF BIOLOGICAL CUT-OFF VALUES FOR PREDICTING RESISTANCE TO THERAPY | VIRCO BVBA (BE) | 2002-04-25 | — | — | WO | claimed |
| WO-2002020057-A2 | FLAVORING SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SUCH COMPOSITIONS | ABBOTT LABORATORIES (US) | 2002-03-14 | — | — | WO | claimed |
| WO-2001097749-A2 | THE USE OF SYNTHETIC, NON-HORMONAL 21-AMINOSTEROIDS AND THEREOF | KOTZE, GAVIN, SALOMON (ZA) | 2001-12-27 | — | — | WO | claimed |
| US-20010051721-A1 | Hydrated forms of lopinavir; HIV protease inhibitor | ABBVIE INC. | 2001-12-13 | — | — | US | claimed |
| WO-2001079246-A2 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS | PHARMASSET, LTD. (BB) | 2001-10-25 | — | — | WO | claimed |
| WO-2001074787-A2 | CRYSTALLINE PHARMACEUTICAL | ABBOTT LABORATORIES (US) | 2001-10-11 | — | — | WO | claimed |